World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 2
Page: 165-178

FAST DISSOLVING FILMS OF NSAIDS: A NOVEL APPROACH FOR RAPID PAIN RELIEF

Tejaram*[1] and Dr. Gaurav Soni[2]

[1]Research Scholar, Lords University, Alwar (Raj.), 301028 India.
[2]Associate Professor Lords University, Alwar (Raj.), 301028 India.

Article Received: 11 February 2025 | | Article Revised: 02 March 2025 | | Article Accepted: 23 March 2025

***Corresponding Author: Tejaram**
Research Scholar, Lords University, Alwar (Raj.), 301028 India.
DOI: https://doi.org/10.5281/zenodo.15112323

How to cite this Article: Tejaram and Dr. Gaurav Soni (2025). FAST DISSOLVING FILMS OF NSAIDS: A NOVEL APPROACH FOR RAPID PAIN RELIEF. World Journal of Pharmaceutical Science and Research, 4(2), 165-178. https://doi.org/10.5281/zenodo.15112323

ABSTRACT

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the management of pain and inflammation. However, conventional oral formulations such as tablets and capsules often suffer from delayed onset of action, gastrointestinal side effects, and poor patient compliance, particularly in elderly and pediatric populations. Fast dissolving films (FDFs) have emerged as a novel drug delivery system that offers rapid drug release, improved bioavailability, and enhanced patient convenience. This review explores the formulation, mechanism of action, and evaluation parameters of NSAID-loaded FDFs, highlighting their advantages over conventional NSAID delivery systems. Various preparation techniques, pharmacokinetic considerations, and regulatory aspects are discussed, along with current challenges and future prospects. The development of NSAID-loaded fast dissolving films represents a promising approach for achieving rapid pain relief while minimizing adverse effects, making them a valuable alternative in pain management.

KEYWORDS: Fast dissolving films, NSAIDs, rapid pain relief, oral drug delivery, bioavailability, formulation techniques, disintegration time, pharmacokinetics, patient compliance, novel drug delivery systems.

1. INTRODUCTION

Pain is one of the most common symptoms associated with various medical conditions, ranging from mild discomfort to severe, debilitating conditions. Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications for pain relief and inflammation management.[1][2] They work by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the synthesis of prostaglandins, thereby reducing pain, fever, and inflammation.

NSAIDs such as ibuprofen, diclofenac, ketorolac, and naproxen are commonly prescribed for conditions like arthritis, musculoskeletal disorders, headaches, and post-operative pain.[3]

Despite their widespread use, conventional NSAID formulations, including tablets, capsules, and injectables, have several limitations. Oral tablets and capsules often have a delayed onset of action due to slow disintegration and absorption, which can be problematic for patients requiring immediate pain relief. Additionally, gastrointestinal irritation, ulceration, and hepatic metabolism can lead to reduced bioavailability and side effects, particularly in long-term use. Parenteral formulations, while effective for rapid action, are invasive and may not be a convenient option for all patients.[4]

To overcome these challenges, novel drug delivery systems such as fast dissolving films (FDFs) have been developed to provide rapid pain relief with enhanced patient compliance. These films are thin, flexible, and dissolve instantly upon contact with saliva, allowing the drug to be rapidly absorbed through the oral mucosa, bypassing first-pass metabolism.[5] This results in faster onset of action, making them particularly beneficial for patients with difficulty swallowing (dysphagia), pediatric and geriatric populations, and those requiring immediate pain relief. The development of NSAID-loaded FDFs presents a promising strategy for enhancing drug efficacy while minimizing side effects, ultimately improving the overall treatment experience for patients.[6][7]

2. Fast Dissolving Films (FDFs): An Innovative Drug Delivery System

Fast dissolving films (FDFs) are an advanced oral drug delivery system designed to dissolve quickly when placed on the tongue or in the buccal cavity, without the need for water. These thin, flexible, and rapidly disintegrating films are made from water-soluble polymers that allow for the immediate release of the active pharmaceutical ingredient (API) upon contact with saliva. FDFs have gained significant attention in recent years due to their potential to enhance drug absorption, improve patient compliance, and provide a convenient alternative to conventional solid dosage forms.[8]

The key mechanism of FDFs lies in their ability to deliver drugs through the oral mucosa, enabling faster absorption into the bloodstream. This bypasses first-pass metabolism, which can enhance bioavailability and lead to quicker onset of therapeutic effects. This is particularly advantageous for drugs like NSAIDs, which are used for pain relief and require rapid action.[9]

Advantages over Conventional Dosage forms

Compared to traditional oral dosage forms such as tablets and capsules, fast dissolving films offer several unique advantages:

Rapid Onset of Action – Since FDFs dissolve instantly in the mouth and absorb through the oral mucosa, the drug reaches systemic circulation faster than conventional tablets or capsules. This makes them ideal for pain relief medications like NSAIDs.

Enhanced Bioavailability – By avoiding gastrointestinal degradation and first-pass metabolism, FDFs can improve drug absorption and lead to higher therapeutic efficacy.

Improved Patient Compliance – Many patients, especially children, elderly individuals, and those with dysphagia (difficulty swallowing), struggle with traditional tablets or capsules. FDFs provide an easy-to-administer alternative.

No Need for Water – Unlike conventional oral dosage forms that require water for swallowing, FDFs dissolve instantly in the mouth, making them convenient for patients on the go or those with restricted water intake.

Reduced Gastrointestinal Side Effects – NSAIDs are known to cause gastric irritation and ulceration. Since FDFs facilitate absorption through the oral mucosa, they may help minimize gastric complications associated with NSAID use.

Portability and Discreet Administration – FDFs are lightweight, compact, and easy to carry, making them an excellent option for pain relief anytime, anywhere. Their discreet nature allows patients to take their medication without attracting attention.

Precise and Uniform Dosing – Unlike syrups or suspensions, where dose measurement errors may occur, FDFs contain a precisely measured drug dose, ensuring accurate and consistent delivery.[9][10]

3. Rationale for Using NSAIDs in Fast Dissolving Films[11][12]

Common NSAIDs Used in Pain Management

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for the treatment of pain, inflammation, and fever. They work by inhibiting cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which is responsible for pain and inflammation. Some commonly used NSAIDs include:

Ibuprofen – Used for mild to moderate pain, fever, and inflammatory conditions such as arthritis.

Diclofenac – Effective for musculoskeletal pain, osteoarthritis, and post-operative pain.

Ketorolac – A potent NSAID used for short-term management of moderate to severe pain.

Naproxen – Preferred for chronic conditions such as rheumatoid arthritis and osteoarthritis.

Celecoxib – A COX-2 selective NSAID used to reduce gastrointestinal side effects.

Aceclofenac – Commonly used in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Challenges with Traditional NSAID Formulations

Despite their therapeutic benefits, conventional NSAID formulations such as tablets, capsules, and injections present several drawbacks:

Delayed Onset of Action – Oral NSAIDs must undergo dissolution and gastric absorption before reaching systemic circulation, leading to a delayed therapeutic effect. This is undesirable for acute pain relief.

Gastrointestinal Irritation – NSAIDs are known to cause gastric mucosal damage, leading to ulcers, gastritis, and gastrointestinal bleeding, especially with prolonged use.

First-Pass Metabolism – Many NSAIDs undergo significant hepatic metabolism, reducing their bioavailability and requiring higher doses, which increases the risk of side effects.

Swallowing Difficulties – Tablets and capsules can be difficult to swallow for pediatric, geriatric, and dysphagic patients, leading to poor compliance.

Inconvenience with Parenteral Administration – Injectable NSAIDs provide rapid pain relief but are invasive, painful, and unsuitable for self-administration.

Given these limitations, a more patient – friendly and efficient drug delivery system is needed, which is where fast dissolving films (FDFs) play a crucial role.

How FDFs Overcome These Challenges

Fast dissolving films (FDFs) provide a novel alternative to traditional NSAID formulations by addressing their key limitations:

Rapid Drug Release & Faster Onset of Action – Since FDFs dissolve instantly in the mouth, the drug is absorbed rapidly through the oral mucosa, leading to quick pain relief compared to conventional oral tablets.

Avoidance of Gastric Irritation – Unlike traditional NSAIDs, which cause gastric irritation, FDFs allow partial drug absorption through the oral mucosa, bypassing the gastrointestinal tract and minimizing side effects.

Bypassing First-Pass Metabolism – Drugs absorbed sublingually or buccally through FDFs enter systemic circulation directly, reducing the need for high doses and improving bioavailability.

Easy Administration & Improved Patient Compliance – FDFs are ideal for children, elderly patients, and individuals with swallowing difficulties, ensuring better adherence to treatment.

No Need for Water or Special Storage – Unlike conventional tablets and capsules, FDFs can be taken anytime, anywhere, making them a portable and convenient option for pain relief.

4. Composition and Formulation of Fast Dissolving Films[13]

The formulation of fast dissolving films (FDFs) involves a delicate balance of components to ensure rapid disintegration, mechanical strength, and efficient drug delivery. The key ingredients in FDFs include polymers, plasticizers, surfactants, sweeteners, and the active pharmaceutical ingredient (API). Each component plays a critical role in the film's performance, including drug stability, dissolution rate, and patient acceptability.

Polymers Used in Film Formulation

Polymers serve as the backbone of fast dissolving films, providing structural integrity and film-forming properties. The choice of polymer influences the mechanical strength, dissolution rate, and drug release profile. Commonly used polymers include:

Hydroxypropyl Methylcellulose (HPMC) – The most widely used polymer due to its excellent film-forming ability, biocompatibility, and rapid disintegration properties.

Polyvinyl Alcohol (PVA) – Provides strong, flexible films with good water solubility and stability.

Sodium Alginate – A natural polymer with bioadhesive properties, enhancing drug retention in the oral cavity.

Pullulan – A polysaccharide known for forming transparent, flexible, and rapidly dissolving films.

Xanthan Gum & Guar Gum – Used as co-polymers to enhance film elasticity and viscosity.

Carboxymethyl Cellulose (CMC) – Improves film wettability and helps in controlled drug release.

Polymers are chosen based on the drug's solubility, stability, and target dissolution time, ensuring fast drug release for immediate pain relief.

Plasticizers, Surfactants, and Sweeteners

To optimize the performance of FDFs, additional excipients are included in the formulation:

Plasticizers (Enhance film flexibility & prevent brittleness)-Glycerol, Propylene Glycol. Polyethylene Glycol (PEG) & Sorbitol

Plasticizers improve the mechanical strength of films, preventing cracking while ensuring a smooth texture.

Surfactants (Enhance drug solubility & dispersion)-Polysorbates (Tween 80, Tween 20), Sodium Lauryl Sulfate (SLS), Lecithin.

Surfactants help in wetting and spreading of the film in saliva, promoting faster drug release and absorption.

Sweeteners & Flavoring Agents (Improve taste and patient acceptability)

- Aspartame, Sucralose, Saccharin (Artificial sweeteners)
- Mannitol, Xylitol, Sorbitol (Sugar alcohols)
- Menthol, Orange, Mint, Strawberry flavors (Mask bitter drug taste)

Since NSAIDs often have a bitter taste, the addition of sweeteners and flavors enhances patient compliance and acceptability, especially in pediatric and geriatric populations.

Drug Loading and Film Thickness Considerations

Drug Loading

The amount of NSAID incorporated into the film is a crucial factor influencing therapeutic efficacy.

Low-dose NSAIDs (Ibuprofen, Ketorolac, Diclofenac) are easier to formulate as FDFs.

High-dose NSAIDs (Naproxen, Celecoxib) may require solubility enhancers or nanotechnology approaches to ensure proper drug dispersion.

The film formulation should allow for uniform drug distribution, ensuring consistent dosing in each strip.

Film Thickness

The thickness of FDFs typically ranges between 50–200 µm, ensuring:

Rapid disintegration in the mouth

Adequate mechanical strength to handle without breaking

Ease of administration and patient comfort

A thinner film dissolves faster but may lack sufficient drug loading, while a thicker film may increase dissolution time. Optimization is necessary for achieving balance between strength and rapid disintegration.[14][15]

5. Methods of Preparation of NSAID-Loaded Fast Dissolving Films[16][17]

The development of fast dissolving films (FDFs) loaded with NSAIDs requires specialized manufacturing techniques to ensure uniform drug distribution, rapid dissolution, and mechanical stability. Several methods are employed for FDF production, with the solvent casting method being the most widely used, followed by hot-melt extrusion and electrospinning for more advanced formulations.

Solvent Casting Method

The solvent casting method is the most commonly used technique for preparing fast dissolving films due to its simplicity, cost-effectiveness, and ability to produce uniform drug dispersion.

Steps Involved

1. Polymer Dissolution – Film-forming polymers (e.g., HPMC, PVA) are dissolved in a suitable solvent (water or ethanol).
2. Drug Incorporation – NSAID is added and dispersed uniformly in the polymer solution.
3. Addition of Excipients – Plasticizers, sweeteners, surfactants, and flavoring agents are mixed in to enhance film properties.
4. Casting – The final solution is poured into a mold or Petri dish and spread evenly to achieve the desired thickness.
5. Drying – The solvent is evaporated under controlled conditions (e.g., hot air drying or vacuum drying) to form a solid, flexible film.

6. Cutting and Packaging – The dried film is cut into strips of uniform size and packed in moisture-resistant packaging.

Advantages

- Ensures uniform drug distribution
- Simple, cost-effective, and scalable
- Suitable for heat-sensitive drugs.

Limitations

- Requires solvent removal, which can be time-consuming
- Solvent residues may affect drug stability.

Hot-Melt Extrusion (HME)

The hot-melt extrusion (HME) technique is a solvent-free method used to improve drug solubility and bioavailability, particularly for poorly water-soluble NSAIDs like celecoxib and naproxen.

Steps Involved

Mixing of Drug and Polymers – NSAID, polymers, plasticizers, and other excipients are mixed in dry form.

Melting & Extrusion – The mixture is heated and passed through an extruder at controlled temperatures.

Film Formation – The molten mass is shaped into thin films using a rolling system.

Cooling & Cutting – The film is cooled rapidly and cut into appropriate sizes.

Advantages

- No solvent required, avoiding residual solvent issues
- Suitable for poorly soluble drugs
- Enhances drug dispersion and bioavailability.

Limitations

- High temperatures may degrade heat-sensitive drugs
- Requires specialized equipment and higher processing costs.

Electrospinning and Other Novel Techniques

Electrospinning is an advanced nanotechnology-based approach that produces ultrafine drug-loaded fibers, which can be processed into fast-dissolving films.

Steps Involved in Electrospinning

- Solution Preparation – A polymer-drug solution is prepared in a suitable solvent.
- Electrospinning Process – The solution is subjected to a high-voltage electric field, which creates fine nano/microfibers.
- Film Formation – The fibers are collected and processed into thin films.

Advantages

- Produces highly porous films with faster drug dissolution.
- Suitable for water-insoluble NSAIDs by increasing surface area.
- Enhances drug stability and bioavailability.

6. Mechanism of Action and Pharmacokinetics[18][19]

The release of NSAIDs from FDFs follows a three-step process:

- Hydration & Disintegration
- Drug Dissolution & Diffusion
- Absorption via Oral Mucosa or Gastrointestinal Tract.

The exact mechanism depends on the NSAID's solubility and permeability. Lipophilic NSAIDs (e.g., diclofenac, celecoxib) may need permeation enhancers to improve mucosal absorption.

One of the primary advantages of FDFs over traditional NSAID formulations is their enhanced bioavailability, achieved through:

- Sublingual & Buccal Absorption
- Rapid Dissolution –
- Avoidance of Gastric Degradation.

Enhanced Permeation – The use of surfactants and permeation enhancers (e.g., polysorbates, bile salts) can improve mucosal absorption of poorly soluble NSAIDs. Comparison with Conventional NSAID Formulations shown in Table 1.

Table 1: Comparison with Conventional NSAID Formulations.[20]

Parameter	Fast Dissolving Films (FDFs)	Tablets/Capsules	Injectables
Onset of Action	5-15 minutes (if buccal absorption occurs)	30-90 minutes (delayed dissolution & gastric absorption)	Immediate (fastest but invasive)
Bioavailability	Higher (mucosal absorption & reduced first-pass metabolism)	Moderate (undergoes first-pass metabolism)	100% (direct systemic circulation)
Patient Compliance	High (easy to administer, no water needed)	Moderate (swallowing difficulty in children/elderly)	Low (painful, requires medical supervision)
Gastrointestinal Side Effects	Reduced (less gastric irritation)	High (risk of ulcers, gastritis)	Low
Convenience & Portability	Very convenient (small, discreet, easy to carry)	Less convenient (requires water for swallowing)	Least convenient (requires sterile conditions)

7. Evaluation Parameters of Fast Dissolving Films

To ensure the efficacy, safety, and quality of NSAID-loaded Fast Dissolving Films (FDFs), various evaluation parameters must be assessed. These include mechanical properties, disintegration and dissolution studies, and drug content uniformity to ensure consistent performance and patient compliance.

Mechanical Properties

The mechanical strength of FDFs is crucial to withstand handling, packaging, and administration without breaking or tearing. The key mechanical parameters include:

Tensile Strength

- Measures the film's ability to resist breaking when stretched.
- Determined using a tensile testing machine by applying force until the film ruptures.
- Higher tensile strength ensures durability and flexibility.

Thickness

- Film thickness should be uniform to ensure consistent drug dosing.
- Measured using micrometers or digital calipers at multiple points.
- Ideal range: 50-200 µm (depending on drug loading and formulation).

Elongation at Break

- Represents the film's flexibility and ability to stretch before breaking.
- Higher elongation indicates better mechanical strength.

Folding Endurance

- Measures film flexibility and resistance to breakage.
- The film is folded repeatedly at the same point until it cracks.
- Higher folding endurance ensures good handling properties.

Disintegration Time and Dissolution Studies

Disintegration Time

- Determines how quickly the FDF breaks apart in saliva.
- Evaluated by placing the film in a petri dish with simulated saliva fluid (pH 6.8, 37°C).
- The time taken for complete disintegration is recorded.
- Ideal range: 5-30 seconds for fast dissolution.

In Vitro Dissolution Studies

- Measures drug release rate from the film.
- Conducted using a USP dissolution apparatus with simulated saliva or gastric fluid.
- Samples are collected at specific intervals, and drug concentration is analyzed using UV-spectrophotometry or HPLC.
- Dissolution profiles should be comparable to or better than conventional NSAID tablets..

Drug Content Uniformity and Stability

Drug Content Uniformity

- Ensures each film strip contains the correct dose of NSAID.
- Multiple film samples are tested using UV spectroscopy or HPLC to measure drug concentration.
- The variation between films should be within ±5% of the labeled dose.

Stability Studies

- Assesses the chemical and physical stability of FDFs over time.
- Stored under ICH-recommended stability conditions (e.g., 25°C/60% RH and 40°C/75% RH).

- Evaluated for changes in appearance, drug content, disintegration time, and mechanical properties over 3-6 months.[21][22]

8. Clinical Efficacy and Safety Considerations

Fast Dissolving Films (FDFs) loaded with NSAIDs are gaining attention due to their rapid onset of action, ease of administration, and improved patient compliance. However, their clinical effectiveness and safety must be established through rigorous preclinical and clinical studies. Additionally, potential side effects must be identified and mitigated to ensure safe usage.

Studies on NSAID-Loaded Fast Dissolving Films

Several research studies and clinical trials have evaluated the efficacy of NSAID-loaded FDFs compared to conventional dosage forms such as tablets and capsules.

Clinical Evidence Supporting NSAID-FDFs

Ibuprofen Fast Dissolving Films

Study Findings

- Faster Tmax (~15-30 min) compared to ibuprofen tablets (~60-90 min).
- Higher bioavailability due to buccal absorption.
- Better patient compliance, especially in pediatric and geriatric populations.
- Conclusion: Effective for rapid pain relief in headaches, fever, and mild to moderate pain.

Ketoprofen FDFs

Study Findings

- Provided rapid dissolution and faster pain relief in arthritis patients.
- Reduced gastric irritation compared to oral tablets.
- Conclusion: Promising alternative to oral NSAID formulations for chronic pain management.

Diclofenac Sodium FDFs

- Study Findings:
- Demonstrated comparable analgesic effect to injectable diclofenac.
- Rapid absorption and fewer GI side effects.
- Conclusion: Could replace oral tablets and injections in emergency pain management.[23]

Potential Side Effects and Mitigation Strategies

Although FDFs improve drug delivery, NSAIDs inherently pose risks such as gastrointestinal (GI) irritation, cardiovascular effects, and hypersensitivity reactions. However, these can be mitigated through formulation strategies. Common Side Effects of NSAID-Loaded FDFs shown in Table 2.

Table 2: Common Side Effects of NSAID-Loaded FDFs.[24][25]

Side Effect	Cause	Mitigation Strategy
Gastrointestinal (GI) Irritation	NSAIDs inhibit prostaglandins, reducing gastric protection.	Use pH-sensitive polymers (e.g., Eudragit) to prevent gastric irritation.
Delayed Ulceration Risk	NSAIDs cause prolonged gastric exposure.	Add gastroprotective agents (e.g., sucralfate, antacids).
Mucosal Irritation in the Oral Cavity	Direct contact of acidic NSAIDs with oral mucosa.	Incorporate mucoadhesive polymers to reduce irritation.
Bitter Taste & Poor Patient Compliance	NSAIDs have an unpleasant taste.	Use flavoring agents (e.g., mint, citrus) & taste-masking technologies.
Cardiovascular Risks (e.g., Hypertension)	Long-term NSAID use may increase blood pressure.	Dose optimization & patient monitoring are necessary.
Hypersensitivity & Allergic Reactions	Some NSAIDs (e.g., aspirin) cause allergic responses.	Avoid in NSAID-sensitive patients; use anti-inflammatory excipients.

Key Safety Enhancements for NSAID-FDFs

- Mucoadhesive polymers reduce direct NSAID exposure to oral mucosa.
- pH-sensitive coatings prevent GI irritation.
- Taste-masking excipients improve patient acceptance.
- Lower-dose formulations minimize cardiovascular risks.

9. Regulatory Aspects and Market Perspectives[26]

The development and commercialization of NSAID-loaded Fast Dissolving Films (FDFs) require compliance with regulatory guidelines to ensure safety, efficacy, and quality. Additionally, understanding the current market scenario and future prospects is crucial for the successful adoption of FDFs in pain management.

FDA and EMA Guidelines for Oral Films

Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines for oral thin films (OTFs) to ensure their quality, safety, and efficacy. Key Regulatory Requirements for Oral Films shown in Table 3.

Table 3: Key Regulatory Requirements for Oral Films.[27]

Regulatory Aspect	FDA Guidelines (U.S.)	EMA Guidelines (Europe)
Classification	Considered oral solid dosage forms	Similar classification as FDA
Formulation Standards	Must meet ICH Q8 (Pharmaceutical Development)	Follows ICH Q8 & Q9 (Quality Risk Management)
Drug Release Criteria	Must comply with USP dissolution standards	Requires in vitro dissolution studies
Bioequivalence Studies	Required for generic FDFs	Needed if different from reference formulation
Stability Testing	Based on ICH Q1A (stability guidelines)	Long-term & accelerated stability studies needed
Labeling Requirements	Must specify dose, route, storage conditions	Similar to FDA requirements

Key Regulatory Challenges

- Ensuring uniform drug content across thin films.
- Demonstrating bioequivalence with existing NSAID formulations.
- Stability concerns due to the hygroscopic nature of films.

Recent FDA Approvals for Fast Dissolving Films

- Ondansetron Oral Film (Zofran®) – First FDA-approved thin-film formulation.
- Diclofenac Sodium Buccal Film – Investigated for rapid pain relief in inflammation-related conditions.

Current Market Trends

- The global oral thin films market was valued at $2.5 billion in 2023 and is projected to grow at a CAGR of ~9% from 2024 to 2030.
- North America dominates the market, followed by Europe and Asia-Pacific, due to increasing preference for non-invasive drug delivery systems.
- Leading pharmaceutical companies investing in oral films include IntelGenx, ZIM Laboratories, and Aquestive Therapeutics.

Market Potential of NSAID-Loaded FDFs

- Growing demand for fast-acting pain relief (e.g., migraines, arthritis).
- Patient-friendly alternative to traditional NSAID tablets and injections.
- Pediatrics and geriatrics benefit from easy administration (no water needed).
- Rising interest in personalized medicine (customized NSAID doses in FDFs).

Future Prospects

Innovations in NSAID-Loaded FDFs

- Nanoformulations & Microparticles – Enhance drug solubility and absorption.
- Smart Polymers & Biodegradable Films – Improve stability and controlled release.
- 3D Printing of Oral Films – Personalized dosing for precision medicine.

Projected Growth Areas

- Combination NSAID Films – Co-formulation with muscle relaxants for pain relief.
- Expansion into Global Markets – Emerging economies (India, China) showing high demand.
- Integration with Digital Health – Smart FDFs that track dosage and patient compliance.

10. Challenges and Future Directions[28]

While Fast Dissolving Films (FDFs) offer a promising alternative for rapid pain relief, they also face certain limitations that need to be addressed. Ongoing research and technological advancements are paving the way for enhanced formulations with improved efficacy, stability, and patient compliance.

Limitations of FDF Technology

Despite their advantages, NSAID-loaded FDFs have some challenges that hinder large-scale adoption:

Formulation Challenges

- Limited Drug Loading Capacity:
- Thin films can only accommodate low drug doses (usually ≤30 mg).
- High-dose NSAIDs (e.g., ibuprofen 400-600 mg) are difficult to incorporate.
- Bitter Taste & Patient Acceptability:

- NSAIDs often have an unpleasant taste, requiring advanced taste-masking.
- Sweeteners and flavors may alter drug release or stability.
- Moisture Sensitivity & Storage Issues:
- FDFs are prone to humidity, affecting film integrity and drug stability.
- Specialized packaging (e.g., aluminum blister packs) increases production costs.

Regulatory & Manufacturing Challenges

- Standardization & Regulatory Hurdles:
- Need for strict content uniformity due to thin film structure.
- Limited bioequivalence studies for NSAID-FDFs compared to tablets/capsules.
- High Production Costs:
- Specialized solvent casting or extrusion techniques required.
- Scale-up difficulties compared to conventional NSAID tablets.

Potential Improvements and Upcoming Research Trends

To overcome these challenges, next-generation FDFs are being developed with advanced materials and novel drug delivery approaches.

- Future Improvements in NSAID-FDFs
- Enhanced Drug Loading Strategies
- Nanotechnology-Based Drug Carriers:
- Nanoemulsions & Lipid Nanoparticles to improve solubility and loading capacity.
- Example: NSAID-loaded nanocrystal FDFs for higher drug content.
- Layered or Multi-Polymer Films:
- Bilayered FDFs can accommodate higher doses without compromising film integrity.
- Example: Ibuprofen dual-layered FDFs for extended pain relief.
- Advanced Taste-Masking Techniques
- Microencapsulation of NSAIDs in polymers to prevent bitter taste perception.
- Ion exchange resins for slow drug release in saliva, reducing bitterness.
- Improved Stability & Packaging
- Smart moisture-resistant coatings for enhanced shelf-life stability.
- Edible biodegradable packaging (e.g., starch-based) for eco-friendly alternatives.
- 3D Printing & Personalized Medicine
- 3D-printed oral films for precise NSAID dosing and patient customization.
- Example: Personalized FDFs for arthritis patients based on pain severity.
- Combination Therapies & Multi-Drug FDFs
- NSAID + Proton Pump Inhibitor (PPI) FDFs to reduce gastric side effects.
- NSAID + Muscle Relaxant FDFs for enhanced pain relief (e.g., diclofenac + thiocolchicoside).[29][30]

11. CONCLUSION

Fast Dissolving Films (FDFs) represent an innovative drug delivery system that offers rapid drug release, enhanced bioavailability, and improved patient compliance compared to traditional NSAID formulations such as tablets and capsules. This review highlights the advantages, formulation strategies, preparation methods, pharmacokinetics, and regulatory considerations of NSAID-loaded FDFs.

Future Outlook on NSAID Fast Dissolving Films

- Nanotechnology & Microparticles: Enhancing drug solubility and bioavailability for higher-dose NSAIDs.
- 3D Printing of FDFs: Enabling customized dosages for personalized medicine.
- Smart Polymers & Biodegradable Films: Improving stability and controlled drug release.
- Combination Therapy FDFs: Co-formulating NSAIDs with gastroprotective agents to minimize side effects.
- Expansion into Global Markets: Increasing patient acceptance and regulatory approvals worldwide.

12. REFERENCES

1. Lodhi DS, Verma M, Golani P, Patra P, Nagdev S, Pawar AS. Fast-dissolving oral film of anti-migraine drug. Nat. J. Pharm, 2021; 1(2): 40-8.
2. Juluru NS. Fast dissolving oral films: A review. Int. J. Adv. Pharm. Biol. Chem, 2013 Jan; 2(1): 108-12.
3. Bhura N, Sanghvi K, Patel U, PARMAR B. A review on fast dissolving film. The International Journal of Pharmaceutical Research and Bio-Science, 2012; 1(3).
4. Singh S, Dixit S, Verma A, Faizan M, Jaiswal N. Fast Dissolving Oral Films: A Review. Int. J. Med. Phar. Drug Re, 2024; 8: 2.
5. Alhamhoom Y, Said AK, Kumar A, Nanjappa SH, Wali D, Rahamathulla M, Farhana SA, Ahmed MM, Shivanandappa TB. Sublingual Fast-Dissolving Thin Films of Loratadine: Characterization, In Vitro and Ex Vivo Evaluation. Polymers, 2024 Oct 17; 16(20): 2919.
6. Bhalse P, Pagare A, Pawar R. A REVIEW ON MOUTH DISSOLVING FILM. J. Int. j. pharm. sci. med, 2024; 9: 82-93.
7. Chaturvedi K, Sharma PK, Dwivedi S, Sharma R, Darwhekar GN. Fast Dissolving Oral Film: An Innovative Approach for Drug Delivery. Current Research in Pharmaceutical Sciences, 2024 Apr 8: 01-9.
8. Singh S, Pawar R, Patidar S. A review on mouth dissolving film-a novel approach. International journal of pharmaceutical sciences and medicine, 2024; 9(2): 36-51.
9. Raihan R, Wafa A, Zhakfar AM, CK S. Oral Disintegrating Films: A Review. Journal of Natural Science Review, 2024 Jun 29; 2(2): 60-74.
10. Zhou J, Wang W, Yang X, Yu DG, Liu P. Electrospun gelatin/tea polyphenol@ pullulan nanofibers for fast-dissolving antibacterial and antioxidant applications. Journal of Food Science, 2024 Nov; 89(11): 7803-18.
11. Ajaykumar Patil. Development and evaluation of fast-dissolving film of montelukast sodium. World Journal of Medical Pharmaceutical and Biological Sciences, 2011: 6-12.
12. Gupta MM, Patel Mitul G, Madhulika Kedawat. Enhancement of dissolution rate of rapidly dissolving oral film of meclizine hydrochloride by complexation of Meclizine hydrochloride with β-cyclodextrine. Journal of Applied Pharmaceutical Science, 2011; 150-153.

13. Prasanthi NL. Design and Development of Sublingual Fast Dissolving Films for an Antiasthmatic Drug. Scholars Research Library, 2011; 382-395.
14. Narasimha Rao R. Formulation and evaluation of rapidly dissolving film Etophylline. International Journal of Pharmacy and Biological Sciences, 2011; 1: 145-159.
15. Dhagla Ram Choudhary. Formulation and Evaluation of Quick Dissolving Film of Ondansetron Hydrochloride. International Journal of Pharmaceutical Research, 2011; 3(4): 31-35.
16. Shelke PV, Dumbare AS, Gadhave MV, Jadhav SL, Sonawanne AA, Gaikwad DD. Formulation and evaluation of rapidly disintegrating film of Amlodipine bedylate. Journal of Drug Delivery & Therapeutics, 2012; 2(2): 72-75.
17. Sapkal NP, Kilor VA, Daud AS, Bonde MN. Development of fast dissolving oral thin films of Ambroxol hydrochloride: Effect of formulation variables. Journal of Advanced Pharmaceutical Research, 2011; 2(2): 102-09.
18. Rowe RC, Sheskey PJ, Owen SC. Hand book of Pharmaceutical Excepients, 2006; 5.
19. Mulla JA, Dasankoppa FS, Vilas GJ, Sholapur HP. Fast dissolving tablets of Promethazine: A novel oral formulation for the treatment of fractionated radiotherapy induced nausea and emesis. Indian drugs, 2008; 45(4): 314-17.
20. Patel DM, Patel MM. Optimization of fast dissolving etorocoxib tablets prepared by sublimation technique. Indian Journal Pharmaceutical Science, 2008; 70(1): 71-76.
21. Swamy PV, Areefulla SH, Shirsand SB, Smitha G, Prashanth B. Orodispersible tablets of meloxicam using disintegrants blends for improved efficacy. Indian Journal of Pharmaceutical Science, 2007; 69(6): 836-40.
22. Babu PS, Chowdary KPR. Enhancement of dissolution rate of celocoxib by solid dispersion in superdisintegrants. Indian drugs, 2007; 45(7): 547-52.
23. Patel DM, Patel MM. Optimization of fast dissolving etorocoxib tablets prepared by sublimation technique. Indian Journal of Pharmaceutical Science, 2008; 70(1): 71-76.
24. Shailesh S, Gupta GD. Formulation and characterization of fast-dissolving tablet of promethazine theoclate. Asian J Pharmaceutics, 2008; 70-72.
25. Mallikarjuna SC, Presad DVK, Gupta VRM, Sa B. Development of fast dispersible aceclofenac tablets: Effect of functionality of superdisintegrants. Indian Journal of Pharmaceutical Science, 2008; 180-84.
26. Santanu C, Madhusmruti K, Satya prakash S, Niranjan CP. Comparative study on effect of natural and synthetic superdisintegrants in the formulation of fast dissolving tablets. International Journal of Green Pharmacy, 2008; 22-25.
27. Ashutosh M, Rajesh KP, Mukesh GC. Formulation, development and evaluation of patient friendly dosage forms of metformin, part-I: Orally disintegrating tablets. Asian Journal of Pharmaceutics, 2008; 167-71.
28. Suresh S, Pandit V, Joshi HP. Preparation and evaluation of mouth dissolving tablets of salbutamol sulphate. Indian Journal of Pharmaceutical Science, 2007; 69(3): 467-69.
29. Shagufta K, Prashant K, Premchand N, Pramod Y. Taste masking of ondansetron hydrochloride by polymer carrier systems and formulation of rapid disintegration tablets. Pharm Sci Tech, 2007; 8(2): E1-E7.
30. Shishu, Ashima B, Tejbir Singh. Preparation of tablets rapidly disintegrating in saliva containing bitter taste-masked granules by compression method. Indian Journal of Pharmaceutical Science, 2007; 69(1): 80-84.